Patient engagement, patient-centric and patient-focused are all terms that are now frequently used in the context of developing new treatments. But what do they mean? There is increasing evidence that effective patient engagement can improve the quality, relevance and success of research but often a lack of support, guidance and training to do so is a barrier to meaningful patient engagement. Many initiatives are now in place both nationally and internationally to break down the barriers to industry and patients working collaboratively to develop new treatments but there is more to be done. European Patients’ Academy of Therapeutic Innovation (EUPATI) is one of many training initiatives that have been developed to support patients to engage and work with the research and development community as well as with regulators and Health Technology Assessment (HTA). To compliment this type of exemplary training, Patient Focused Medicines Development (PFMD) and Parkinson’s UK have worked with a group of stakeholders including patients, pharmaceutical representatives, researchers and experts in the field of patient engagement to develop a practical and interactive training session to support industry representatives to work with patients.
This workshop will present evidence that patient engagement improves medicines research and development processes and benefits the stakeholders involved when done right, draw on case studies of best practice, and tackle practical questions of how to effectively involve patients to produce more targeted outcomes.
Topics to be covered:
• What do we mean by patient engagement and why is everyone talking about it?
• When to involve patients in R&D and how?
• What do we know about the practical impact of patient engagement?
• Planning your own patient engagement.
• What support and resources are available?
Who should attend:
Anyone involved in the planning and design of research studies and clinical trials, and in particular, those who are not sure where to start patient involvement and engagement in medicines development continuum. This may also be suitable for people responsible for patient involvement and engagement as a tool to support their work.
What will you gain from attending?
The participants in the workshop will gain an understanding of the importance of involving patients in developing ideas in different aspects of research. They will gain some insight into the challenges and benefits of working with patients as well as practical information, advice and tools into how to meaningfully work with patients in this way.
Claire Nolan, Research Involvement Manager, Parkinson's UK
Nicholas Brooke, Chief Executive, PFMD (Patient Focused Medicines Development) and The Synergist
David Gray, Senior Director, Neuroscience Research Unit, Pfizer, USA